Levisonics is developing a novel platform for haemostatic assays that delivers more accurate and repeatable measurements using a fraction of the sample size compared to currently available technologies. This has huge implications for both pediatrics and home monitoring, two areas where large sample size requirements have historically been a barrier.
Home monitoring is an especially pressing problem to address. There are over 40 million annual prescriptions for anticoagulants (blood thinners) and no reliable methods for self monitoring. For older adults, anticoagulants (warfarin in particular) were implicated in 33% of emergency hospitalizations for adverse drug events. [https://www.nejm.org/doi/full/10.1056/NEJMsa1103053]